New concepts in HIV-1 vaccine development.

TitleNew concepts in HIV-1 vaccine development.
Publication TypeJournal Article
Year of Publication2016
AuthorsStephenson KE, D'Couto HT, Barouch DH
JournalCurr Opin Immunol
Volume41
Pagination39-46
Date Published08/01/2016
ISSN1879-0372
Abstract

With 2 million people newly infected with HIV-1 in 2014, an effective HIV-1 vaccine remains a major public health priority. HIV-1 vaccine efficacy trials in humans, complemented by active and passive immunization studies in non-human primates, have identified several key vaccine-induced immunological responses that may correlate with protection against HIV-1 infection. Potential correlates of protection in these studies include V2-specific, polyfunctional, and broadly neutralizing antibody responses, as well as effector memory T cell responses. Here we review how these correlates of protection are guiding current approaches to HIV-1 vaccine development. These approaches include improvements on the ALVAC-HIV/AIDSVAX B/E vaccine regimen used in the RV144 clinical trial in Thailand, adenovirus serotype 26 vectors with gp140 boosting, intravenous infusions of bNAbs, and replicating viral vectors.

DOI10.1016/j.coi.2016.05.011
Alternate JournalCurr. Opin. Immunol.
PubMed ID27268856
Grant ListR01 OD011170 / OD / NIH HHS / United States
U19 AI078526 / AI / NIAID NIH HHS / United States
U19 AI095985 / AI / NIAID NIH HHS / United States
U19 AI096040 / AI / NIAID NIH HHS / United States
UM1 AI100663 / AI / NIAID NIH HHS / United States
UM1 AI124377 / AI / NIAID NIH HHS / United States
CHAVI-ID: 
1
Cover Picture: